Summary of treatment recommendations for allogeneic HCT for Hodgkin lymphoma
| Recommendation . | |
|---|---|
| Most patients who relapse after autologous HCT will receive CPIs rather than conventional therapy. | |
| Allogeneic HCT should be used instead of conventional therapy for relapse after autologous HCT. | |
| RIC is the recommended regimen intensity. | |
| All donor sources (except cord blood) can be considered. | |
| PTCy-based GVHD prophylaxis is considered standard and is preferred in patients with prior CPI. | |
| Allogeneic HCT can be considered in patients as soon as they achieve CR after CPI but is typically deferred to relapse/progression or because of lack of response or intolerance. | |
| DLI can be given for relapse or progressive disease (limited data for mixed-donor chimerism). | |
| Recommendation . | |
|---|---|
| Most patients who relapse after autologous HCT will receive CPIs rather than conventional therapy. | |
| Allogeneic HCT should be used instead of conventional therapy for relapse after autologous HCT. | |
| RIC is the recommended regimen intensity. | |
| All donor sources (except cord blood) can be considered. | |
| PTCy-based GVHD prophylaxis is considered standard and is preferred in patients with prior CPI. | |
| Allogeneic HCT can be considered in patients as soon as they achieve CR after CPI but is typically deferred to relapse/progression or because of lack of response or intolerance. | |
| DLI can be given for relapse or progressive disease (limited data for mixed-donor chimerism). | |
DLI, donor lymphocyte infusion.
Adapted with permission from Perales et al.9